Psychosexual morbidity in women with ovarian cancer.
gynecology
ovarian cancer
ovarian neoplasms
ovary
quality of life (PRO)/palliative care
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
28
08
2020
revised:
07
10
2020
accepted:
07
10
2020
pubmed:
30
10
2020
medline:
2
10
2021
entrez:
29
10
2020
Statut:
ppublish
Résumé
Increasing numbers of women are surviving for longer with epithelial ovarian cancer. Consequently, there is increased focus on long-term quality of life in national guidance. Psychosexual morbidity including vaginal dryness, pain during intercourse (dyspareunia), reduced libido, and negative perceived body image exacerbate stress and anxiety and impact intimate relationships. Although a priority for women with epithelial ovarian cancer, clinicians seldom discuss sexual problems. Therefore, psychosexual morbidity and the associated distress remain unaddressed. We synthesize evidence from primary qualitative and quantitative research studies exploring psychosexual morbidity in women with epithelial ovarian cancer to identify potential risk factors and common symptoms, to facilitate the identification and management of sexual problems in clinic. Literature (2008-19) from 10 databases identified 29 suitable publications (4116 patients). The papers were assessed to answer the question: "What are the key potential risk factors and presentations of psychosexual morbidity in women with epithelial ovarian cancer?" Current literature lacks consensus in defining clinically significant psychosexual morbidity in women with epithelial ovarian cancer. Discrepancies in measurement tools, questionnaires, and primary outcome measures confound result interpretation, limiting wider application. Key potential risk factors identified included: younger age (<53 years); pre-menopausal status at diagnosis; aim of treatment; extent of surgery; more courses of chemotherapy; cardiovascular co-morbidities; and anxiety and depression. Up to 75% of women with epithelial ovarian cancer reported adverse changes in their sex lives following diagnosis and, of the sexually active, vaginal dryness affected 81-87% and pain 77%. Other prevalent symptoms included: reduced sexual desire and activity, impaired orgasm, diminished perceived body image, and reduced partner intimacy. Psychosexual morbidity represents a significant unmet need for women with epithelial ovarian cancer. Effective treatment necessitates a multimodal approach encompassing medical, psychoeducational, and physiotherapy-based strategies. Future studies need agreement in their questionnaires, definitions, thresholds, and primary outcome measures for meaningful interstudy comparisons to be drawn.
Identifiants
pubmed: 33115791
pii: ijgc-2020-002001
doi: 10.1136/ijgc-2020-002001
pmc: PMC7788483
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1983-1989Informations de copyright
© IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Gynecol Oncol. 2017 Aug;146(2):386-391
pubmed: 28602549
Cochrane Database Syst Rev. 2020 Jan 28;1:CD012559
pubmed: 31989588
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Gynecol Oncol. 2017 Nov;147(2):433-438
pubmed: 28888542
Menopause. 2016 Mar;23(3):335-42
pubmed: 26308232
Gynecol Oncol. 2012 Apr;125(1):59-64
pubmed: 22155797
Oncol Nurs Forum. 2011 Nov;38(6):699-708
pubmed: 22037332
Cancer Nurs. 2009 Jul-Aug;32(4):271-80
pubmed: 19444088
Gynecol Oncol. 2017 Jul;146(1):101-108
pubmed: 28527672
J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208
pubmed: 10782451
Psychooncology. 2013 Jul;22(7):1565-71
pubmed: 22936668
Gynecol Oncol. 2016 Nov;143(2):367-370
pubmed: 27531571
Oncology. 2016;91(4):205-210
pubmed: 27513866
Gynecol Oncol. 2009 Aug;114(2):353-9
pubmed: 19481244
Sex Med. 2019 Dec;7(4):530-539
pubmed: 31501030
Qual Life Res. 1996 Feb;5(1):81-90
pubmed: 8901370
Health (London). 2009 Sep;13(5):523-41
pubmed: 19696134
Eur J Oncol Nurs. 2013 Jun;17(3):381-5
pubmed: 23200482
Lancet Oncol. 2018 Dec;19(12):1680-1687
pubmed: 30413383
Climacteric. 2015 Feb;18(1):94-8
pubmed: 25029389
Cancer. 2009 Nov 15;115(22):5237-42
pubmed: 19645027
Eur J Oncol Nurs. 2017 Oct;30:8-14
pubmed: 29031318
Gynecol Oncol. 2004 Mar;92(3):827-32
pubmed: 14984948
J Obstet Gynaecol Can. 2014 Aug;36(8):708-715
pubmed: 25222166
Br J Cancer. 2003 Mar 10;88(5):666-71
pubmed: 12618871
Arch Sex Behav. 2017 Oct;46(7):2059-2083
pubmed: 28039595
Am J Obstet Gynecol. 2017 Oct;217(4):395-403
pubmed: 28411144
Eur J Oncol Nurs. 2010 Apr;14(2):137-46
pubmed: 19836305
Gynecol Oncol. 2015 Oct;139(1):148-54
pubmed: 26291650
J Gynecol Oncol. 2015 Apr;26(2):148-54
pubmed: 25686396
Gynecol Oncol. 2008 Feb;108(2):348-54
pubmed: 17996925
Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1183-93
pubmed: 18217977
Eur J Cancer Care (Engl). 2016 Mar;25(2):280-93
pubmed: 25040442